Literature DB >> 10076542

Inhibition by aminosalicylates of phosphatidic acid formation induced by superoxide, calcium or spermine in enterocyte mitochondria.

M Madesh1, K A Balasubramanian.   

Abstract

Inflammation is associated with oxidative stress and altered cellular calcium homeostasis. Our earlier studies have shown that, increased phosphatidic acid (PA) formation occurred in enterocyte mitochondria when exposed to superoxide, divalent metal ions or polyamines resulting in altered lipid composition. Since aminosalicylates are the drug of choice for gut inflammation, we have tested the effect of aminosalicylates on PA formation by enterocyte mitochondria. When stimulated by superoxide, Ca2+ or spermine, phosphatidyleth-anolamine (PE) degradation and PA formation occurred in enterocyte mitochondria which can be inhibited by aminosalicylates. The inhibition was 50-60% at 0.5-mM concentration and at 1- or 2-mM final concentration, complete inhibition was observed. Both 5-aminosalicylate (5-ASA) and 4-aminosalicylate (4-ASA) showed similar effects. The stimulation of PA formation by calcium or spermine was not due to increased generation of superoxide by mitochondria which was confirmed by measurement of superoxide production by the mitochondria. These studies suggest that in addition to other cellular effects, aminosalicylates may prevent the enterocyte mitochondrial damage by inhibition of PA formation and PE degradation and alteration of mitochondrial lipid composition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10076542     DOI: 10.1016/s0006-2952(97)00642-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  1 in total

1.  Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without causing gastric side effects in a rat model of colitis.

Authors:  Gabriella Varga; Melinda Ugocsai; Petra Hartmann; Norbert Lajkó; Réka Molnár; Szilárd Szűcs; Dávid Kurszán Jász; Dániel Érces; Miklós Ghyczy; Gábor Tóth; Mihály Boros
Journal:  Inflammopharmacology       Date:  2017-04-27       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.